Compugen (NASDAQ: CGEN) and Brainstorm Cell Therapeutics (NASDAQ:BCLI) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their risk, analyst recommendations, profitability, valuation, dividends, institutional ownership and earnings.
Institutional & Insider Ownership
19.4% of Compugen shares are owned by institutional investors. Comparatively, 8.0% of Brainstorm Cell Therapeutics shares are owned by institutional investors. 9.5% of Compugen shares are owned by insiders. Comparatively, 23.7% of Brainstorm Cell Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
Analyst Ratings
This is a summary of current recommendations for Compugen and Brainstorm Cell Therapeutics, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Compugen | 0 | 0 | 1 | 0 | 3.00 |
| Brainstorm Cell Therapeutics | 0 | 0 | 1 | 0 | 3.00 |
Compugen currently has a consensus target price of $14.00, suggesting a potential upside of 317.91%. Brainstorm Cell Therapeutics has a consensus target price of $8.00, suggesting a potential upside of 91.39%. Given Compugen’s higher possible upside, research analysts clearly believe Compugen is more favorable than Brainstorm Cell Therapeutics.
Valuation and Earnings
This table compares Compugen and Brainstorm Cell Therapeutics’ revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | EBITDA | Earnings Per Share | Price/Earnings Ratio | |
| Compugen | $123,000.00 | 1,392.59 | -$33.14 million | ($0.67) | -5.00 |
| Brainstorm Cell Therapeutics | N/A | N/A | -$4.96 million | ($0.27) | -15.48 |
Brainstorm Cell Therapeutics has higher revenue, but lower earnings than Compugen. Brainstorm Cell Therapeutics is trading at a lower price-to-earnings ratio than Compugen, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares Compugen and Brainstorm Cell Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Compugen | -4,425.00% | -57.69% | -50.83% |
| Brainstorm Cell Therapeutics | N/A | -49.12% | -44.58% |
Volatility & Risk
Compugen has a beta of 0.61, suggesting that its share price is 39% less volatile than the S&P 500. Comparatively, Brainstorm Cell Therapeutics has a beta of 2.29, suggesting that its share price is 129% more volatile than the S&P 500.
Summary
Brainstorm Cell Therapeutics beats Compugen on 7 of the 10 factors compared between the two stocks.
Compugen Company Profile
Compugen Ltd. is a therapeutic discovery company. The Company focuses on infrastructure to discover drug targets and develop therapeutics. The Company is engaged in the research, development and commercialization of therapeutic and product candidates. The Company’s pipeline primarily consists of early and preclinical stage immuno-oncology programs based on drug targets discovered by the Company, primarily immune checkpoint and myeloid protein target candidates. These programs are focused on the development of cancer immunotherapy drugs with potential to harness the immune system to provide treatment solutions in areas of unmet medical needs in various cancer types and patient populations, both as monotherapy and in combination with other drugs. Its pipeline also includes a preclinical stage fusion protein autoimmune product candidate. Its fields of focus are oncology and immunology, with emphasis on its discovery capabilities on immuno-oncology.
Brainstorm Cell Therapeutics Company Profile
Brainstorm Cell Therapeutics Inc. is a biotechnology company. The Company is engaged in developing adult stem cell therapies for debilitating neurodegenerative disorders, such as Amyotrophic Lateral Sclerosis (ALS, also known as Lou Gehrig’s disease), Multiple Sclerosis (MS) and Parkinson’s disease (PD), among others. Its subsidiary, Brainstorm Cell Therapeutics Ltd. (the Israeli Subsidiary), holds rights to commercialize the technology, NurOwn. NurOwn is in clinical development for the treatment of ALS. The Company has completed over two clinical trials of NurOwn in patients with ALS at Hadassah Medical Center (Hadassah). The first study, a Phase I/II safety and efficacy study of NurOwn in ALS patients administered either intramuscularly or intrathecally. The Company conducted Phase IIa combined (intramuscular and intrathecal) treatment, dose-escalating trial. It had completed treatment of over 10 patients in its ALS Phase IIa NurOwn dose-escalating clinical trial.
Receive News & Ratings for Compugen Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Compugen Ltd. and related companies with MarketBeat.com's FREE daily email newsletter.
